Skip to content
PIL Logo

Bricanyl Injection, 0.5 mg/ml, solution for injection or infusion

Last Updated on eMC 27-Apr-2017 View document  | AstraZeneca UK Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 27-Apr-2017 and displayed until Current

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - driving and using machines
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 28-May-2015 and displayed until 27-Apr-2017

Reasons for adding or updating:

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 06-Mar-2014 and displayed until 28-May-2015

Reasons for adding or updating:

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - use in children/adolescents
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 3 - how to take/use
  • Change to section 3 - duration of treatment
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Change to section 1 - what the product is used for

Updated on 19-Nov-2013 and displayed until 06-Mar-2014

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 24-Dec-2010 and displayed until 19-Nov-2013

Reasons for adding or updating:

  • Change of manufacturer

Updated on 08-Apr-2009 and displayed until 24-Dec-2010

Reasons for adding or updating:

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 21-Oct-2008 and displayed until 08-Apr-2009

Reasons for adding or updating:

  • Change due to user-testing of patient information

Updated on 26-Jul-2004 and displayed until 21-Oct-2008

Reasons for adding or updating:

  • Improved Electronic Presentation

Updated on 04-Sep-2002 and displayed until 26-Jul-2004

Reasons for adding or updating:

  • Update to PIL

Updated on 14-Sep-2000 and displayed until 04-Sep-2002

Reasons for adding or updating:

  • No reasons supplied

Company contact details

AstraZeneca UK Limited

Company image
Address

Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU

Fax

+44 (0)1582 838 000

Medical Information e-mail
Medical Information Fax

+44 (0)1582 838 003

Telephone

+44 (0)1582 836 000

Medical Information Direct Line

0800 783 0033

Customer Care direct line

+44 (0)1582 837 837

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

terbutaline sulfate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue